Copernicus Announces Issuance of Gene Targeting Patent.Business Editors, Health/Medical Writers CLEVELAND--(BW HealthWire)--March 14, 2001 Copernicus Therapeutics Inc. announced that the United States Patent Office has issued Serpin Enzyme Complex Receptor (SECR SECR South Eastern & Chatham Railway SECR Subway & Erie Canal Revitalization (Rochester, NY) SECR Sophisticated Electronic Cash Register SECR Squared Error-Correction Radius SECR Standard Embedded Computer Resource )-Mediated Gene Transfer, US Patent Number 6,200,801. Mark Cooper, M.D., senior vice president of Science and Medical Affairs said, "This patent, issued to Case Western Reserve University and licensed exclusively by Copernicus, further expands our ability to target various tissues for DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. transfer by reciting composition claims for fusion proteins that consist of SECR targeting ligands and polycations capable of binding to DNA. These composition claims extend coverage of issued U.S. patent 5,972,901, which provides formulation and in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. DNA delivery methods for SECR-targeted compacted DNA complexes. Our compacted DNA particles are stable in physiologic fluids, and facilitate receptor-mediated uptake into cells and transfer across the nuclear membrane nuclear membrane n. The double-layered membrane enclosing the nucleus of a cell. Also called nuclear envelope. . SECR-positive tissues include hepatocytes, hematopoietic cells Hematopoietic cells Those cells that are lodged within the bone marrow, and which are responsible for producing the cells which circulate in the blood (red blood cells, white blood cells, and platelets). Mentioned in: Aplastic Anemia , certain epithelial cells Epithelial cells Cells that form a thin surface coating on the outside of a body structure. Mentioned in: Corneal Transplantation , glial cells, and neurons, providing a robust platform for diverse clinical indications such as gene therapies for hemophilia, Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. , or cystic fibrosis." "Copernicus, through its association with Case Western Reserve University, has established a very broad and enabling position in the field of targeted and non-targeted non-viral gene therapy," said Robert C. Moen, M.D., Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Copernicus. "Our intellectual property positions us uniquely in this field. Given the dangers inherent with viral vectors, our technology enables us to access the favorable aspects of viral vectors while providing the safety and pharmaceutical qualities inherent in non-viral gene delivery systems. We expect to broadly partner our delivery platforms with others wishing to exploit the advantages of our proprietary technologies." Copernicus Therapeutics Inc. is advancing novel targeting and delivery systems with broad applications in human therapeutics and vaccines. Copernicus' technologies include a multi-component delivery platform that can be applied to nucleic acids to develop therapies for a variety of human diseases and a targeting platform enabling the efficient uptake of drugs by specific cells and tissues. The company's targeting and delivery platforms are complimentary and can be combined to enhance the efficacy and safety of existing drugs or to create novel therapeutics. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion